Dipen

[Dipen @Dipenkmodi]

Please join us at the 7th Annual Lymphoma Symposium organized on August 2, 2025. Outstanding speakers will review the latest data and spark thought provoking discussions.

Registration link: https://t.co/wOOmwifXYD

[Graham Collins @graham74GC]

Liso-cel 2ary CNS lymphoma: Ahmed
- 57 pts, 39 wth active CNSL at infn
- ORR 73%, 12mo PFS 30%, 45% 12mo OS
- no diff if active or not active CNSL
- 16% G3/4 ICANs (?higher than for other liso-cel data)
#ASH24 #lymsm

[Dipen @Dipenkmodi]

@MediHumdani @CatherineLeeMD @mshadman @hemant_murthy Nice work! Clinically very helpful!

[Graham Collins @graham74GC]

Lee et al: SGN35-027 AN+AD in adv cHL 1L
- ph2, n=57, primary EP CMR
- med 35y, 50% stage 4
- no FN, 56% PN with 4% G3
- ORR/CMR 95%/89%
- PFS at 2y 88%
- 1 each of: colitis, pneumonitis, T1 DM, hypophysitis
- 7 imAEs discontinued nivo
#ASH23 #lymsm

[Mehdi Hamadani, MD @MediHumdani]

If you see an eligible DLBCL patient in CR, does #CART outperform AutoHCT? Only available data by @CIBMTR @mshadman Reminds you to keep an open mind,
one size does not fit all 🙏🙏 @ASH_hematology for recognizing our work in Press Release #ASH23

[Dipen @Dipenkmodi]

@AsmitaShukla01 Well deserved! Congrats! Great job!

[Dipen @Dipenkmodi]

Great to contribute to this important study of Mosunetuzumab and Polatuzumab in RR DLBCL. ASH abstract#613 @ash2023. @karmanoscancer. Feel free to check out this simultaneous publication in nature Medicine. https://t.co/9WgoJo6wyr

[Abhinav Deol @abhinav_deol]

#ASH23 @AsmitaShukla01 @KarmanosHemeOnc @Dipenkmodi @karmanoscancer will present our data about outcomes of older pts who unergo AlloHSCT for MDS/AML . Poster 3612

[Blood Journals Portfolio @BloodPortfolio]

Time-limited triple therapy leads to high rates of undetectable minimal residual disease and sustained remissions in high-risk CLL. https://t.co/IVpHcHJoWR

[Richa Parikh @richaparikh36]

Join us tomorrow, Aug 12th, Sat at 7PM CST to chat about how to navigate through Heme-Onc fellowship interviews!!! Thank you @drtulsijose @ascobhsetx for inviting me!

Sign up now:
https://t.co/TOZd2nGfno

[Abhinav Deol @abhinav_deol]

Transplantation in Management of Lymphoma by @primouberti at the Lymphoma Symposium organized by @Dipenkmodi @karmanoscancer

[Abhinav Deol @abhinav_deol]

Primary CNS Lymphoma management by Dr. Ramchandren @karmanoscancer Lymphoma Symposium organized by @Dipenkmodi

[Abhinav Deol @abhinav_deol]

A very thoughtful presentation by @CraigMoskMD on Hodgkin disease @karmanoscancer Lymphoma Symposium @Dipenkmodi

[Abhinav Deol @abhinav_deol]

Dr. Iyer gave a great presentation about managent of T cell Lymphomas at the @karmanoscancer Lymphoma symposium @Dipenkmodi

[Abhinav Deol @abhinav_deol]

Excellent talk by Dr. Leonard on managment of Mantle cell lymphoma @karmanoscancer Lympohma Symposium @Dipenkmodi

[Abhinav Deol @abhinav_deol]

Dr. Jay Yang @karmanoscancer presenting about Follicullar Lymphoma at the Annual Lymphoma Symposium orgabized by @Dipenkmodi

[Karmanos Hematology/Oncology Fellowship @KarmanosHemeOnc]

Don’t miss the 2023 Lymphoma Symposium on Saturday, July 29th by our fantastic team @karmanoscancer
@JayYang41413741 @abhinav_deol @primouberti Dr. Charles Schiffer, chaired by @Dipenkmodi

Register now at https://t.co/qS3jPfApXy

Key note speakers: @CraigMoskMD @JohnPLeonardMD

[Dipen @Dipenkmodi]

S1826- Nivo+ AVD significantly improved PFS compared to BV+AVD and will become a standard of care for advanced Hodgkin lymphoma. The combination was well tolerated and rate of consolidation radiation therapy was considerably low.

[Abhinav Deol @abhinav_deol]

Please mark your calendar to attend The 5th Annual Lymphoma Symposium organized by @Dipenkmodi @karmanoscancer to learn about updates in management of various lymphomas.

[Dipen @Dipenkmodi]

Dr. Shah talking about relapsed refractory Hodgkin lymphoma. @btfoundation @hrshah1